Literature DB >> 19882303

Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.

Michael Makris1, Joost J van Veen, Rhona Maclean.   

Abstract

The management of patients with supra-therapeutic INR in a common clinical problem. The risk of bleeding is influenced by the intensity, variability and duration of anticoagulation, patient age, presence of co-morbidities and concomitant drug therapy. For the asymptomatic patient, warfarin discontinuation is all that is usually required but for individuals at high risk of bleeding and those with INR > 10, oral vitamin K administration is recommended. In the presence of major bleeding, treatment with intravenous vitamin K and prothrombin complex concentrate is the most effective therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19882303     DOI: 10.1007/s11239-009-0412-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  67 in total

1.  The use of oral vitamin K for reversal of over-warfarinization.

Authors:  K Pendry; M Bhavnani; K Shwe
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

2.  What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008.

Authors:  Rachel P Rosovsky; Mark A Crowther
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

3.  Use of factor IX complex in warfarin-related intracranial hemorrhage.

Authors:  N M Boulis; M P Bobek; A Schmaier; J T Hoff
Journal:  Neurosurgery       Date:  1999-11       Impact factor: 4.654

4.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

5.  The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.

Authors:  Jeffrey J Glasheen; Randolph V Fugit; Allan V Prochazka
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

6.  Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.

Authors:  E M Hylek; Y C Chang; S J Skates; R A Hughes; D E Singer
Journal:  Arch Intern Med       Date:  2000-06-12

7.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

8.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

9.  Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation.

Authors:  R J Patel; D M Witt; J J Saseen; D J Tillman; D S Wilkinson
Journal:  Pharmacotherapy       Date:  2000-10       Impact factor: 4.705

Review 10.  Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.

Authors:  Kirsten Neudoerffer Kangelaris; Stephen Bent; Robert L Nussbaum; David A Garcia; Jeffrey A Tice
Journal:  J Gen Intern Med       Date:  2009-03-21       Impact factor: 5.128

View more
  17 in total

Review 1.  Prothrombin complex concentrates: an update.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

2.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

3.  Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal?

Authors:  Mike Makris; Joost J Van Veen
Journal:  Blood Transfus       Date:  2011-01-13       Impact factor: 3.443

Review 4.  [Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

Authors:  S M Schellong; H Riess; M Spannagl; H Omran; M Schwarzbach; F Langer; W Gogarten; P Bramlage; R M Bauersachs
Journal:  Internist (Berl)       Date:  2018-07       Impact factor: 0.743

Review 5.  [Bridging anticoagulation in patients receiving vitamin K antagonists : Current status].

Authors:  S M Schellong; H Riess; M Spannagl; H Omran; M Schwarzbach; F Langer; W Gogarten; P Bramlage; R M Bauersachs
Journal:  Anaesthesist       Date:  2018-08       Impact factor: 1.041

Review 6.  Characterizing the Severe Reactions of Parenteral Vitamin K1.

Authors:  Rachel B Britt; Jamie N Brown
Journal:  Clin Appl Thromb Hemost       Date:  2016-10-21       Impact factor: 2.389

7.  Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.

Authors:  Priccila Zuchinali; Gabriela C Souza; Graziella Aliti; Mariana R Botton; Lívia Goldraich; Katia G Santos; Mara H Hutz; Eliane Bandinelli; Luis E Rohde
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

8.  Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy.

Authors:  Peter Toth; Joost Jair van Veen; Kate Robinson; Rhona Murray Maclean; Kingsley Kevin Hampton; Stuart Laidlaw; Michael Makris
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

9.  Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis.

Authors:  Hidetaka Arishima; Ayumi Tada; Makoto Isozaki; Ryuhei Kitai; Toshiaki Kodera; Ken-ichiro Kikuta; Katsunori Tai; Hiromichi Iwasaki
Journal:  J Spinal Cord Med       Date:  2014-06-29       Impact factor: 1.985

10.  Prothrombin complex concentrates in warfarin anticoagulation reversal.

Authors:  Carolina Costa-Lima; Maiara Marx Luz Fiusa; Joyce M Annichino-Bizzacchi; Erich Vinicius de Paula
Journal:  Rev Bras Hematol Hemoter       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.